Abstract:What's new? In hepatocellular carcinoma, downregulation of TRIM21 within the tumor has been associated with poor survival prognosis. Unmasking the underlying mechanisms could help assess the therapeutic value of TRIM21. Here, the authors compared the pathophysiological evolution of non‐alcoholic steatohepatitis leading to liver cancer in an hypoinsulinemic mouse model with and without TRIM21 expression. TRIM21 deficiency aggravated the development of hepatocellular carcinoma, which correlated with increased expression of the immune checkpoints PD‐1 and PD‐L1 in the spleen and liver and in hepatocellular carcinoma tumors. The findings suggest that TRIM21 may promote antitumor surveillance via the downregulation of inhibitory immune checkpoints. The global pandemic of metabolic diseases has increased the incidence of hepatocellular carcinoma (HCC) in the context of non‐alcoholic steatohepatitis (NASH). The downregulation of the E3 ubiquitin ligase TRIM21 has been linked to poor prognosis in different cancers including HCC. In order to investigate the role of TRIM21 in liver cancer progression on NASH, Trim21+/+ and Trim21−/− male mice were injected with streptozotocin at the neonatal stage. The hypoinsulinemic mice were then fed with a high‐fat high‐cholesterol diet (HFHCD) for 4, 8 or 12 weeks. All mice developed NASH which systematically resulted in HCC progression. Interestingly, compared to the Trim21+/+ control mice, liver damage was worsened in Trim21−/− mice, with more HCC nodules found after 12 weeks on HFHCD. Immune population analysis in the spleen and liver revealed a higher proportion of CD4+PD‐1+ and CD8+PD‐1+ T cells in Trim21−/− mice. The liver and HCC tumors of Trim21−/− mice also exhibited an increase in the number of PD‐L1+ and CD68+ PD‐L1+ cells. Thus, TRIM21 limits the emergence of HCC nodules in mice with NASH by potentially restricting the expression of PD‐1 in lymphocytes and PD‐L1 in tumors.

Tripartite motif-containing protein 31 confers protection against nonalcoholic steatohepatitis by deactivating mitogen-activated protein kinase kinase kinase 7.

TRIM31 confers protection against nonalcoholic steatohepatitis by deactivating MAP3K7

Tripartite motif 16 ameliorates nonalcoholic steatohepatitis by promoting the degradation of phospho-TAK1

Tripartite motif containing 26 prevents steatohepatitis progression by suppressing C/EBPδ signalling activation

Comprehensive profiling of the TRIpartite motif family to identify pivot genes in hepatocellular carcinoma

The E3 ubiquitin-protein ligase Trim31 alleviates non-alcoholic fatty liver disease by targeting Rhbdf2 in mouse hepatocytes

Tripartite motif 38 alleviates the pathological process of NAFLD/NASH by promoting TAB2 degradation

Terf2ip Deficiency Accelerates Non-Alcoholic Steatohepatitis Through Regulating Lipophagy and Fatty Acid Oxidation Via Sirt1/AMPK Pathway

TRIM56 Protects Against Nonalcoholic Fatty Liver Disease by Promoting the Degradation of Fatty Acid Synthase.

The E3 ligase tripartite motif 8 targets TAK1 to promote insulin resistance and steatohepatitis.

Tripartite Motif 31 Promotes Resistance to Anoikis of Hepatocarcinoma Cells Through Regulation of P53-Ampk Axis

Inflammation-induced TRIM21 represses hepatic steatosis by promoting the ubiquitination of lipogenic regulators

Protectin D1 Inhibits TLR4 Signaling Pathway to Alleviate Non-Alcoholic Steatohepatitis Via Upregulating IRAK-M.

E3 ubiquitin ligase TRIM31: A potential therapeutic target

TRIM31 is Upregulated in Hepatocellular Carcinoma and Promotes Disease Progression by Inducing Ubiquitination of TSC1–TSC2 Complex

Tripartite Motif‐Containing 27 Attenuates Liver Ischemia/Reperfusion Injury by Suppressing Transforming Growth Factor β–Activated Kinase 1 (TAK1) by TAK1 Binding Protein 2/3 Degradation

Peroxisome Proliferator-Activated Receptor Γ Coactivator 1α Maintains NAD+ Bioavailability Protecting Against Steatohepatitis

TRIM31: A Molecule with a Dual Role in Cancer

Trim21 deficiency in mice increases HCC carcinogenesis in a NASH context and is associated with immune checkpoint upregulation

TRIM29 modulates proteins involved in PTEN/AKT/mTOR and JAK2/STAT3 signaling pathway and suppresses the progression of hepatocellular carcinoma

Tripartite motif‐containing protein 11 promotes hepatocellular carcinogenesis through ubiquitin‐proteasome–mediated degradation of pleckstrin homology domain leucine‐rich repeats protein phosphatase 1